Minimal Residual Disease (MRD) in Colorectal Cancer (CRC)
Learn from industry leading GI oncology experts in this educational, three-part series on minimal residual disease (MRD) in colorectal cancer (CRC), followed by an open Q&A session. Attendees will learn how these experts use ctDNA and MRD assessment to guide treatment decisions, and identify patients who are at risk for recurrence following curative intent therapy.
Each session will be led by a leading CRC medical oncologist: Scott Kopetz MD, PhD, FCAP, is the Deputy Chair, GI Medical Oncology, and Del and Dennis McCarthy Distinguished Professor at MD Anderson Cancer Center. Dr. Kopetz also serves as the Chair of the NCI Colon Task Force. Pashtoon Kasi, MD, MS, is an Assistant Professor of Medicine at Weill Cornell Medical College. Bassel El-Rayes, MD, is the Deputy Director at The University of Alabama at Birmingham. He also serves as the director of the Division of Hematology & Oncology in the Heersink School of Medicine’s Department of Medicine.